Heart Doc VIP with Dr. Joel Kahn cover image

Episode 485: What's the Hoopla About Nattokinase?

Heart Doc VIP with Dr. Joel Kahn

00:00

Large Chinese study has major limitations

Joel Kahn critiques a 1,062-person open-label Chinese study promoted online, noting no placebo and manufacturer conflicts of interest.

Play episode from 16:54
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app